Atrix Laboratories, Inc. has announced that its subsidiary, Atrix Laboratories, GmbH has hired 10 experienced dental sales representatives to market Atridox(TM) periodontal disease product in Germany.
"Germany represents an excellent market opportunity for Atridox in Europe," said David R. Bethune, Atrix's chairman and chief executive officer. "In order to maximize our opportunity, we decided to promote Atridox ourselves in this important marketplace."
Atridox combines the company's Atrigel(R) drug delivery system with the antibiotic doxycycline to dramatically reduce the bacteria associated with periodontal disease. The innovative treatment is applied as a gel to the affected area, where it conforms to the shape of the periodontal pocket and solidifies, releasing doxycycline over a period of about seven days as it bioabsorbs.
In order to optimize the reimbursement situation in Germany, Atrix recently received approval to sell one and two packets of Atridox rather than the six-packs, which had previously been submitted and approved by the German regulatory authorities.